“I do think the watch out that we all need to watch carefully is certainly the impact of the recently announced IV saline shortages, which if they do persist, could potentially impact surgical procedures across our portfolio.”

In context

“ich also, by the way, we've added indication of the [Uni Knee] (ph), as well as our KINCISE and Hip Navigation systems within hips. I'd also add to the Orthopaedics performance, we are significantly addressing portfolio gaps within our trauma portfolio with the launch of TriLeap, [indiscernible] and VOLT in the back half of the year. And I think you know our spine portfolio has been challenged, and we're addressing that with the launch of TELIGEN, our new TriALTIS thoracal lumbar system and the new spine robot, which we just received approval for. As it relates the hurricanes, we did see the impact, certainly of Hurricane Helene, in the final weeks of the third quarter and continue to see the impact of Milton over the last coming days especially in the areas most impacted by those storms. I do think the watch out that we all need to watch carefully is certainly the impact of the recently announced IV saline shortages, which if they do persist, could potentially impact surgical procedures across our portfolio. Thank you, Larry. Operator: Thank you. Next question is coming from Louise Chen from Cantor Fitzgerald. Your line is now live. Louise Chen: Hi. Thank you for taking my question here. I wanted to ask you how you see TREMFYA, JNJ-2113 and some of your other pipeline products coming together to replace sales lost to STELARA and then take share from entrenched competitors? Thank you. Jennifer Taubert: Hi. Louise. It's Jennifer. And good morning, everyone. And I wanted to start off by having a chance to really recognize and thank all my Innovative Medicine colleagues around the world for fabulous quarter in the third quarter. We really continue to deliver against our strategy with 11 key brands having double-digit growth and achieving a few really notable milestones, notably the TREMFYA approv”